Symbol | Exchange | Currency |
|---|
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more...
Biotech stocks snapped back from their weekly losses and ended higher for the week ended March 12, with the broader market recovery partly aiding the reversal.Entera Bio Ltd....
Galmed Pharmaceuticals announces the pricing of the underwritten public offering of 2.19M shares for gross proceeds of about $10M.The offering is expected to close...
Galmed Pharmaceuticals (GLMD) is a clinical-stage biopharmaceutical company focused on developing Aramchol, a stearoyl-coenzyme A desaturase‑1 (SCD1) modulator that targets the...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was a big mover last session, as the company saw its shares rise more than 8% on the day. The move came on solid volume too with far...
The promising but challenging indication of nonalcoholic steatohepatitis (NASH) hit headlines following two major developments.Firstly, the frontrunner in the NASH space, Intercept...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Neutral | Sell | Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Buy | Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Buy | Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,660.30 | 2,668.00 | 2,596.00 | +91.9 | +3.58% | 2.08M | ||||
| 369.79 | 375.33 | 357.19 | +18.60 | +5.30% | 33.69M | ||||
| 586.35 | 595.48 | 583.76 | -0.53 | -0.09% | 628.25K | NASDAQ | |||
| 227.80 | 227.98 | 226.13 | +1.59 | +0.70% | 261.07K | NYSE | |||
| 42.90 | 43.06 | 42.47 | +0.20 | +0.47% | 331.84K | ||||
| 7.90 | 7.98 | 7.55 | 0.000 | 0.00% | 0.00 | NASDAQ | |||
| 3.15 | 3.20 | 2.99 | +0.050 | +1.61% | 83.23K | NASDAQ | |||
| 176.27 | 176.74 | 174.89 | +1.39 | +0.79% | 201.22K | NASDAQ | |||
| 28.15 | 28.21 | 27.93 | +0.14 | +0.50% | 30.23M | NYSE | |||
| 26.29 | 26.99 | 26.01 | +0.40 | +1.54% | 604.61K | ||||
| 29.06 | 29.06 | 28.35 | +0.71 | +2.50% | 7.97K | OTC Markets | |||
| 44.34 | 44.92 | 43.74 | -0.06 | -0.14% | 99.06K | ||||
| 9.72 | 9.72 | 9.68 | +0.080 | +0.83% | 2.28K | NASDAQ | |||
| 60.11 | 61.28 | 59.80 | -0.37 | -0.61% | 4.69M | NYSE | |||
| 291.27 | 292.37 | 288.19 | +2.31 | +0.80% | 2.08M | NYSE |
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.
